Pathophysiology of chronic graft-versus-host disease and therapeutic targets
Chronic GVHD, an autoimmune disease that follows allogeneic hematopoietic-cell
transplantation, is characterized by infections and debilitating tissue injury leading to …
transplantation, is characterized by infections and debilitating tissue injury leading to …
[HTML][HTML] The biology of chronic graft-versus-host disease: a task force report from the National Institutes of Health Consensus Development Project on Criteria for …
KR Cooke, L Luznik, S Sarantopoulos, FT Hakim… - Biology of Blood and …, 2017 - Elsevier
Chronic graft-versus-host disease (GVHD) is the leading cause of late, nonrelapse mortality
and disability in allogeneic hematopoietic cell transplantation recipients and a major …
and disability in allogeneic hematopoietic cell transplantation recipients and a major …
Ibrutinib for chronic graft-versus-host disease after failure of prior therapy
Chronic graft-versus-host disease (cGVHD) is a serious complication of allogeneic stem cell
transplantation with few effective options available after failure of corticosteroids. B and T …
transplantation with few effective options available after failure of corticosteroids. B and T …
The role of extracorporeal photopheresis in the management of cutaneous T‐cell lymphoma, graft‐versus‐host disease and organ transplant rejection: a consensus …
A Alfred, PC Taylor, F Dignan… - British journal of …, 2017 - Wiley Online Library
Extracorporeal photopheresis (ECP) has been used for over 35 years in the treatment of
erythrodermic cutaneous T‐cell lymphoma (CTCL) and over 20 years for chronic and acute …
erythrodermic cutaneous T‐cell lymphoma (CTCL) and over 20 years for chronic and acute …
Chronic graft-versus-host disease detected by tissue-specific cell-free DNA methylation biomarkers
B Avni, D Neiman, E Shaked… - The Journal of …, 2024 - Am Soc Clin Investig
BACKGROUND. Accurate detection of graft-versus-host disease (GVHD) is a major
challenge in the management of patients undergoing hematopoietic stem cell …
challenge in the management of patients undergoing hematopoietic stem cell …
Toward a better understanding of the atypical features of chronic graft-versus-host disease: a report from the 2020 National Institutes of Health Consensus Project …
GDE Cuvelier, M Schoettler, NP Buxbaum… - … and cellular therapy, 2022 - Elsevier
Alloreactive and autoimmune responses after allogeneic hematopoietic cell transplantation
can occur in nonclassical chronic graft-versus-host disease (chronic GVHD) tissues and …
can occur in nonclassical chronic graft-versus-host disease (chronic GVHD) tissues and …
[HTML][HTML] Low-dose IL-2 selectively activates subsets of CD4+ Tregs and NK cells
Abstract CD4+ regulatory T cells (CD4Tregs) play a critical role in the maintenance of
immune tolerance and prevention of chronic graft-versus-host disease (GVHD) after …
immune tolerance and prevention of chronic graft-versus-host disease (GVHD) after …
Plasma cell polarization to the immunoglobulin G phenotype in hepatocellular carcinomas involves epigenetic alterations and promotes hepatoma progression in …
Y Wei, XM Lao, X Xiao, XY Wang, ZJ Wu, QH Zeng… - Gastroenterology, 2019 - Elsevier
Background & Aims Little is known about the composition and generation of plasma cell
subsets in patients with hepatocellular carcinoma (HCC) and how these associate with …
subsets in patients with hepatocellular carcinoma (HCC) and how these associate with …
Immune profile differences between chronic GVHD and late acute GVHD: results of the ABLE/PBMTC 1202 studies
KR Schultz, A Kariminia, B Ng… - Blood, The Journal …, 2020 - ashpublications.org
Human graft-versus-host disease (GVHD) biology beyond 3 months after hematopoietic
stem cell transplantation (HSCT) is complex. The Applied Biomarker in Late Effects of …
stem cell transplantation (HSCT) is complex. The Applied Biomarker in Late Effects of …
Plasma biomarkers of risk for death in a multicenter phase 3 trial with uniform transplant characteristics post–allogeneic HCT
M Abu Zaid, J Wu, C Wu, BR Logan… - Blood, The Journal …, 2017 - ashpublications.org
A phase 3 clinical trial (BMT CTN 0402) comparing tacrolimus/sirolimus (Tac/Sir) vs
tacrolimus/methotrexate (Tac/Mtx) as graft-versus-host disease (GVHD) prophylaxis after …
tacrolimus/methotrexate (Tac/Mtx) as graft-versus-host disease (GVHD) prophylaxis after …